" class="no-js "lang="en-US"> KD Pharma Group Acquires Phytoextract and CBD Manufacturing Assets - Medtech Alert
Sunday, March 26, 2023

Breaking News

Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa Celyad Oncology Appoints Georges Rawadi as Its New CEO Companion Spine Closes $60.1 Million Series A Funding Round EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing Led by Gilde Healthcare Genprex CEO Commends FDA’s Initiative to Accelerate Approval Process for Gene Therapies OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases
KD Pharma Acquires Phytoextract and CBD Manufacturing Assets | Pharmtech Focus

April 12 2021

KD Pharma Group Acquires Phytoextract and CBD Manufacturing Assets

The KD Pharma Group has acquired the manufacturing assets of a Swiss-based cannabinoid manufacturer. The assets give KD Pharma access to technology for producing Active Pharmaceutical Ingredients (APIs) based on phytocannabinoids and other plant extracts. The technology further expands KD’s lipid technology portfolio and can be used in combination with KD’s other fractionation and separation technologies.

“KD Pharma is a leader in lipid technology focused primarily on omega-3s, but our technology suite has applications in other lipid sources like cannabinoids,” said Oscar Groet, CEO of the KD Pharma Group. “We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts,” Groet continued, “and these assets give KD Pharma additional pathways to develop new products for this emerging market.”

The Group has also licensed a novel extraction method from Herbolea Biotech S.r.l. and expects to have a complete, licensed cGMP manufacturing facility online by the end of the year.

  1. Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa

    Diseases

     Read more
  2. Celyad Oncology Appoints Georges Rawadi as Its New CEO

    Appointments

     Read more
  3. Companion Spine Closes $60.1 Million Series A Funding Round

    Fundraising

     Read more
  4. EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis

    News

     Read more
  5. Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer

    Appointments

     Read more
More On